Molecule to Market: Inside the outsourcing space

The Puzzle-Solving Lifelong Science Geek

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:

• How a family ritual of solving puzzles played a role in developing an entrepreneurial spirit of problem solving
• Learn about how and why Northern Texas is becoming a destination for biotech and life sciences
• Going viral for being viral... and why covid was the time for immunologists to shine
• The opportunities and challenges of introducing innovative, disruptive technology into the biopharma space

Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund.

Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the chair for the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The CDMO with a capital D

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Harry Christiaens, CEO at Ardena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Harry, covering:

• How a regulatory change led a small consultancy down the path of becoming one of Europe’s most respected mid-sized CDMOs
• The easy-theory of an M&A buy-and-build strategy, versus the challenging practical realities after acquiring and integrating five businesses
• Key considerations and questions you should ask before selecting a private equity partner
• The role of nano-technology in producing nanomedicines for effective targeting of disease…but also the challenges of dealing with this enabling platform
• Why there is cause for optimization for CDMOs when looking at the robust R&D funding environment and forecasted outsourcing growth

Harry has significant leadership experience with 20+ years in the pharma and biotech industry. He successfully transformed Pharmavize, a regulatory consultancy company into a leading CDMO, establishing a GMP team and infrastructure from scratch. Since 2015, he led the acquisitions and integration of five companies providing highly complementary services. He successfully integrated the service offering of the acquired companies onto one platform, creating the Ardena brand.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

100 episodes of Molecule to Market: looking back, lessons & laying the land for 101

In this special episode of Molecule to Market, we are marking our 100th episode! Join us as we look back, review our learnings and lay the land for episode 101…

For those that have been here since the beginning, we are incredibly grateful for your constant support and feedback. To our new listeners, thank you for joining the journey, seeing us through to 30,000 downloads and beyond. 

To our guests - thank you for being a part of this experience with us and taking the time to share your story. The podcast wouldn’t be what it is without the incredible guests we have come and grace the M2M microphone. With even more amazing thought leaders on the horizon and a special celebration coming to DCAT Week, stay tuned for a jam-packed 2023...

Your host, Raman Sehgal, switches seats with journalist Dan Stanton as host for a celebration of 100 episodes of the podcast. They discuss;

• The Molecule to Market journey and how the podcast has evolved
• Raman’s experience with securing a private equity deal for sponsor of the podcast, ramarketing, the business he started in 2009 
• Valuable lessons learnt throughout the process including; how to get the best out of a guest, what didn’t work so well as the podcast evolved and breaking the podcast formula 
• What’s to come for the podcast and Raman in 2023 and beyond…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Raman’s review of life science in 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the last 12 months in the life science industry.

He covers his 5 key trends from the year including:

• The biotech capital market slowdown and its impact on the outsourcing space
• Sustainability as the hot topic within the sector, from events to company practices
• Businesses operating in an increasingly digital way and what that means for the tech companies supporting them
• The cooling of mergers and acquisitions activity in the life sciences industry
• A reduction of discussion around Covid-19 as it moves into the sector’s rear view
  
  

Come back in 2023 for brand new episodes with great guests, including a special 100th episode celebration. Also, if you’re a previous guest, keep an eye out for an exclusive invitation in your inbox very soon…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

A blast from the life science past

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with a look back to some of our early guests from the Molecule to Market archive.

Your host, Raman Sehgal, recaps his discussions on the pharmaceutical and biotechnology supply chain with:

• Stefano Console, founder and Senior Advisor at Oriento discussing: founding his business in Switzerland and the fractional management staffing structure that is helping Oriento succeed
• Claire Thompson, founder and CEO of Agility Life Sciences discussing: her career as a footballer and how it has helped her when successfully leading a team
• Jitesh Devendra, Managing Director at Solara Active Pharma Sciences discussing:  why it is crucial to invest time internally to be just as operationally focused as you are strategically focused
• Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics discussing: her do’s and don’ts for building new business partnerships

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Tackling the 3 Big C’s: CDMO Career, Children & Cancer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering:
 
Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer.
Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective.
The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond.
Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment
 
Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient’s unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo’d drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization.
 
Located in Boston, MA, Sarah’s experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University.
 
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
 
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Mystic Miller’s review of ’22 and predictions for ’23

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Top 5 episodes of all time

As we celebrate the podcast hitting 30,000 downloads and approaching its 100th episode, Raman reflects on the most downloaded episodes with highlights from the top 5.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector, diving into the top 5 episodes of all time, featuring:

• JoyL Silva, Pfizer CentreOne discussing: her early career journey and advice, industry trends, and personalized medicines
• Tia Lyles-Williams, LucasPye Bio discussing: equality & diversity, Covid-19’s impact, fundraising and providing opportunities to the next generation  
• Gerry Cox, Velesco Pharma Services discussing: client relationships, starting a new business and his advice 
• Cory Lewis, INCOG BioPharma discussing: acquisitions, turning around a business, and lessons from the franchise model 
• Allan Shaw, Industry Consultant discussing: biotech trends, commonalities & challenges, and the supply chain ecosystem

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

CPHI 2022 - Trends, challenges & opportunities

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:

• Grainne Hughes, Vice President of Business Support Operations at Almac 
• Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
• Guido Wallraff, Corporate Business Development Director at Ardena
• Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
• Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma

Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Views from AAPS 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

• Casey Franklin, VP of Business Development at Alcami

• Umberto Romeo, R&D Manager at Corden Pharma

• Steven Dodd, Executive Director for sales strategy at Icon CRO

• Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.